Victor Woolf (Royal College of Surgeons Examinations Assessor)
Yolanda Woolf (Risk and Governance Consultant, Ret. NHS Associate Director, Governance, Risk and Compliance)
The UroPharma direct to bladder universal drug delivery device addresses the off-license use of catheters and systematic drug administration risks yet keeps the basic familiarity of a catheter with a drainage channel and balloon to retain the device in the bladder.
The fundamental design change introduces a revolutionary dedicated drug delivery channel with non-return valve and the facility to close the drainage channel at the catheter tip, making this a safe and effective universal medication direct to bladder, drainage, irrigation, and drug delivery technology.
Laurence Stewart MD FRCSEd FRCS(urol)Ed (Consultant Urological Surgeon)
The introduction of UroPharma intravesical drug delivery allows for bladder emptying via a large drainage channel, which is then closed off prior to drug instillation via a second small lumen (small volume) channel without breaching sterility or instilling via a contaminated channel.
When this intravesical drug delivery system becomes commercially available it will no longer be acceptable to use single lumen catheters for this purpose and I would expect that the regulatory authorities would rapidly move to outlaw their use.